Research Analysts Set Expectations for Amgen FY2025 Earnings

Amgen Inc. (NASDAQ:AMGN) – Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Amgen in a research report issued on Tuesday, January 21st. Cantor Fitzgerald analyst O. Brayer expects that the medical research company will post earnings per share of $21.44 for the year. Cantor Fitzgerald has a “Overweight” rating and a $405.00 price objective on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.57 per share.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.11 by $0.47. The firm had revenue of $8.50 billion during the quarter, compared to the consensus estimate of $8.50 billion. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The business’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.96 EPS.

Other equities research analysts have also issued research reports about the stock. Bank of America restated an “underperform” rating and set a $256.00 price target on shares of Amgen in a research note on Tuesday, December 10th. Wolfe Research began coverage on Amgen in a research note on Friday, November 15th. They issued a “peer perform” rating on the stock. Barclays increased their price target on Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a research note on Monday, October 7th. UBS Group lowered their price objective on Amgen from $335.00 to $326.00 and set a “neutral” rating on the stock in a research note on Thursday, October 31st. Finally, Wells Fargo & Company reduced their target price on shares of Amgen from $335.00 to $280.00 and set an “equal weight” rating for the company in a research note on Friday, January 10th. Two research analysts have rated the stock with a sell rating, twelve have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $314.91.

Amgen Price Performance

AMGN opened at $277.88 on Wednesday. The firm has a market cap of $149.37 billion, a P/E ratio of 35.58, a PEG ratio of 2.79 and a beta of 0.56. The company has a debt-to-equity ratio of 7.55, a quick ratio of 0.96 and a current ratio of 1.32. Amgen has a fifty-two week low of $253.30 and a fifty-two week high of $346.85. The firm has a 50-day moving average of $271.91 and a 200 day moving average of $306.43.

Hedge Funds Weigh In On Amgen

Hedge funds and other institutional investors have recently modified their holdings of the company. Capital Performance Advisors LLP bought a new stake in Amgen in the 3rd quarter worth approximately $25,000. Legacy Investment Solutions LLC bought a new stake in shares of Amgen in the 3rd quarter worth approximately $29,000. Hershey Financial Advisers LLC purchased a new stake in shares of Amgen in the 2nd quarter valued at $30,000. Matrix Trust Co purchased a new position in Amgen in the 3rd quarter worth $36,000. Finally, Heck Capital Advisors LLC bought a new stake in Amgen in the fourth quarter worth $36,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, February 14th will be given a dividend of $2.38 per share. This is an increase from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.43%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.